Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 12/20 | 0.48 |
| ▸ | BRAF | P15056 | 1/20 | 0.45 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.42 |
| ▸ | PIK3C3 | Q8NEB9 | 3/20 | 0.42 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.40 |
| ▸ | WNT3A | P56704 | 1/20 | 0.40 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.39 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16864218 | 0.83 | PIK3C3 (0.48) | NAMPTBRAFPIK3C3 | |
| SCHEMBL160863 | 0.83 | NAMPT (0.44) | NAMPTBRAFPSMD14PIK3C3 | |
| SCHEMBL29511927 | 0.83 | NAMPT (0.44) | NAMPTBRAFPSMD14PIK3C3 | |
| SCHEMBL30908106 | 0.80 | HPGDS (0.49) | NAMPTPSMD14 | |
| SCHEMBL15116371 | 0.80 | PSMD14 (0.49) | NAMPTPSMD14PIK3C3 | |
| SCHEMBL6226865 | 0.80 | NAMPT (0.51) | NAMPT | |
| SCHEMBL29930392 | 0.80 | PIK3C3 (0.52) | PIK3C3 | |
| SCHEMBL12673417 | 0.79 | PIK3C3 (0.45) | NAMPTBRAFPIK3C3 | |
| SCHEMBL12647974 | 0.79 | NAMPT (0.41) | NAMPTBRAFPIK3C3 | |
| SCHEMBL28600744 | 0.79 | NAMPT (0.45) | NAMPTBRAFPIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3994138-A1 | ESTROGEN-RELATED RECEPTOR ALPHA (ERRalpha) MODULATORS | Lead Pharma Holding B.V. (NL) | 2022-05-11 | — | — | EP | claimed |
| WO-2021001453-A1 | ESTROGEN-RELATED RECEPTOR ALPHA (ERRα) MODULATORS | LEAD PHARMA HOLDING B.V. (NL) | 2021-01-07 | — | — | WO | claimed |
| EP-2820017-B1 | PYRIDINYL AND PYRIMIDINYL SULFOXIDE AND SULFONE DERIVATIVES | GENENTECH INC (US) | 2016-12-21 | — | — | EP | claimed |
| US-20110105491-A1 | THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-05-05 | — | — | US | claimed |
| US-20080269123-A1 | Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases | STOWERS MEDICAL INSTITUTE INC. | 2008-10-30 | — | — | US | claimed |
| EP-1021413-B1 | THE PREPARATION AND USE OF ORTHO-SULFONAMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | WYETH CORP (US) | 2003-06-11 | — | — | EP | claimed |
| EP-1021413-A1 | THE PREPARATION AND USE OF ORTHO-SULFONAMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | American Cyanamid Company (US) | 2000-07-26 | — | — | EP | claimed |
| WO-1999018076-A1 | THE PREPARATION AND USE OF ORTHO-SULFONAMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1999-04-15 | — | — | WO | claimed |
| WO-1998016514-A1 | ORTHO-SULFONAMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1998-04-23 | — | — | WO | claimed |
| EP-0361382-A2 | Antiepileptic pyrazolopyridines | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-04-04 | — | — | EP | claimed |
| EP-3710428-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4655300-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | Epirium Bio Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20250313574-A1 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2025-10-09 | — | — | US | disclosed |
| US-20250268877-A1 | 2H-INDAZOLE DERIVATIVES AS IRAK4 INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASE | BIOGEN MA INC. | 2025-08-28 | — | — | US | disclosed |
| US-12336981-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| WO-1999018076-A1 | THE PREPARATION AND USE OF ORTHO-SULFONAMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1999-04-15 | — | — | WO | disclosed |
| WO-1998016514-A1 | ORTHO-SULFONAMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1998-04-23 | — | — | WO | disclosed |
| EP-0361382-A2 | Antiepileptic pyrazolopyridines | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-04-04 | — | — | EP | disclosed |
| US-4038283-A | ANTIINFLAMMATORY AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1977-07-26 | — | — | US | disclosed |
| US-3983128-A | CNS DEPRESSANTS, ANTIINFLAMMATORY | E. R. SQUIBB & SONS, INC. (US) | 1976-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105491-A1 | THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | MGAM 4522/4885NAMPT 977/4885BRAF 4346/4885 |
| US-20250268877-A1 | 2H-INDAZOLE DERIVATIVES AS IRAK4 INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASE | IRAK4, IRAK3, IRAK2 | MGAM 3947/4885NAMPT 3466/4885BRAF 132/4885 |
| US-12336981-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NNT | MGAM 1669/4885NAMPT 1/4885BRAF 3005/4885 |
| US-20250313574-A1 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | NEU1, NEU2, NEU4 | MGAM 193/4885NAMPT 216/4885BRAF 4753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.